Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10255865 | 0.80 | NNMT (0.44) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL23620229 | 0.80 | POLB (0.38) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL12116625 | 0.79 | MAPT (0.38) | P2RX7 | |
| SCHEMBL13233495 | 0.78 | NNMT (0.40) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL21620863 | 0.78 | POLB (0.37) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL12060293 | 0.78 | POLB (0.37) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL31010430 | 0.76 | NNMT (0.41) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL3671439 | 0.76 | APLNR (0.44) | NNMTPOLBTDP1CYP1A2KMT2A | |
| SCHEMBL13952702 | 0.74 | CCR1 (0.39) | CYP1A2KMT2AP2RX7 | |
| SCHEMBL10196024 | 0.73 | NNMT (0.39) | NNMTPOLBTDP1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-7572806-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-7491831-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7476746-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080096913-A1 | PPAR active compounds | PLEXXIKON, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7348338-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2008-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096913-A1 | PPAR active compounds | PPARG, PPARD, PPARA | NNMT 1138/4885POLB 1093/4885TDP1 3738/4885 |
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | NNMT 98/4885POLB 308/4885TDP1 4367/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | NNMT 1138/4885POLB 1093/4885TDP1 3738/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | NNMT 1791/4885POLB 483/4885TDP1 346/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | NNMT 1922/4885POLB 3938/4885TDP1 4683/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | NNMT 2011/4885POLB 3823/4885TDP1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.